S&P 500   3,095.50 (+0.12%)
DOW   27,755.55 (+0.23%)
QQQ   201.58 (+0.02%)
CGC   18.76 (-2.55%)
BABA   182.41 (-2.44%)
GE   11.33 (-0.88%)
T   39.17 (+0.00%)
F   8.88 (-1.77%)
ACB   3.51 (-1.68%)
BAC   32.81 (-0.85%)
DIS   145.00 (+4.63%)
S&P 500   3,095.50 (+0.12%)
DOW   27,755.55 (+0.23%)
QQQ   201.58 (+0.02%)
CGC   18.76 (-2.55%)
BABA   182.41 (-2.44%)
GE   11.33 (-0.88%)
T   39.17 (+0.00%)
F   8.88 (-1.77%)
ACB   3.51 (-1.68%)
BAC   32.81 (-0.85%)
DIS   145.00 (+4.63%)
S&P 500   3,095.50 (+0.12%)
DOW   27,755.55 (+0.23%)
QQQ   201.58 (+0.02%)
CGC   18.76 (-2.55%)
BABA   182.41 (-2.44%)
GE   11.33 (-0.88%)
T   39.17 (+0.00%)
F   8.88 (-1.77%)
ACB   3.51 (-1.68%)
BAC   32.81 (-0.85%)
DIS   145.00 (+4.63%)
S&P 500   3,095.50 (+0.12%)
DOW   27,755.55 (+0.23%)
QQQ   201.58 (+0.02%)
CGC   18.76 (-2.55%)
BABA   182.41 (-2.44%)
GE   11.33 (-0.88%)
T   39.17 (+0.00%)
F   8.88 (-1.77%)
ACB   3.51 (-1.68%)
BAC   32.81 (-0.85%)
DIS   145.00 (+4.63%)
Log in

GlobeImmune Stock Price, Forecast & Analysis (OTCMKTS:GBIM)

$0.07
0.00 (0.00 %)
(As of 11/13/2019 01:36 PM ET)
Today's Range
$0.07
Now: $0.07
$0.07
50-Day Range
$0.07
MA: $0.08
$0.10
52-Week Range
$0.04
Now: $0.07
$0.25
Volume9,000 shs
Average Volume21,908 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta0.43
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GBIM
Previous SymbolNASDAQ:GBIM
CUSIPN/A
Phone303-625-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees2
Next Earnings DateN/A
OptionableNot Optionable

Receive GBIM News and Ratings via Email

Sign-up to receive the latest news and ratings for GBIM and its competitors with MarketBeat's FREE daily newsletter.


GlobeImmune (OTCMKTS:GBIM) Frequently Asked Questions

What is GlobeImmune's stock symbol?

GlobeImmune trades on the OTCMKTS under the ticker symbol "GBIM."

How were GlobeImmune's earnings last quarter?

GlobeImmune Inc (OTCMKTS:GBIM) announced its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.12. The biopharmaceutical company earned $0.94 million during the quarter. View GlobeImmune's Earnings History.

Has GlobeImmune been receiving favorable news coverage?

News articles about GBIM stock have been trending very negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GlobeImmune earned a news impact score of -3.2 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for GlobeImmune.

Who are some of GlobeImmune's key competitors?

What other stocks do shareholders of GlobeImmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlobeImmune investors own include OHR Pharmaceutical (OHRP), Novavax (NVAX), Premier Gold Mines (PG), Algonquin Power & Utilities (AQN), Nordic American Tanker (NAT), PETROLEO BRASIL/ADR (PBR), Pengrowth Energy (PGH), Banro (BAA), Orocobre (ORE) and DryShips (DRYS).

Who are GlobeImmune's key executives?

GlobeImmune's management team includes the folowing people:
  • Mr. C. Jeffrey Dekker CPA, Pres, VP of Fin., Treasurer, Sec. and Director (Age 54)
  • Dr. Richard C. Duke, Scientific Founder & Member of Scientific Advisory Board
  • Dr. Donald Bellgrau, Scientific Founder & Chairman of The Scientific Advisory Board
  • Mr. Thomas A. Keuer, Acting Head of Manufacturing Operations (Age 60)
  • Dr. Allen L. Cohn M.D., Exec. Director Clinical Devel. (Age 61)

How do I buy shares of GlobeImmune?

Shares of GBIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GlobeImmune's stock price today?

One share of GBIM stock can currently be purchased for approximately $0.07.

What is GlobeImmune's official website?

The official website for GlobeImmune is http://www.globeimmune.com/.

How can I contact GlobeImmune?

GlobeImmune's mailing address is 1450 INFINITE DRIVE, LOUISVILLE CO, 80027. The biopharmaceutical company can be reached via phone at 303-625-2700 or via email at [email protected]


MarketBeat Community Rating for GlobeImmune (OTCMKTS GBIM)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about GlobeImmune and other stocks. Vote "Outperform" if you believe GBIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel